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Pten deficiency depletes hematopoietic stem cells
(HSCs) but expands leukemia-initiating cells, and
the mTOR inhibitor, rapamycin, blocks these effects.
Understanding the opposite effects of mTOR activa-
tion on HSCs versus leukemia-initiating cells could
improve antileukemia therapies. We found that the
depletion of Pten-deficient HSCs was not caused
by oxidative stress and could not be blocked by
N-acetyl-cysteine. Instead, Pten deletion induced,
and rapamycin attenuated, the expression of
p16Ink4a and p53 in HSCs, and p19Arf and p53 in other
hematopoietic cells. p53 suppressed leukemogen-
esis and promotedHSCdepletion afterPten deletion.
p16Ink4a also promoted HSC depletion but had a
limited role suppressing leukemogenesis. p19Arf
strongly suppressed leukemogenesis but did not
deplete HSCs. Secondary mutations attenuated this
tumor suppressor response in some leukemias that
arose after Pten deletion. mTOR activation therefore
depletes HSCs by a tumor suppressor response
that is attenuated by secondary mutations in leuke-
mogenic clones.
INTRODUCTION
Phosphatidylinositol 3-kinase (PI3-kinase) pathway signaling
promotes cell growth, proliferation, and survival by several
mechanisms (see Figure S1 available online for a schematic;
Wullschleger et al., 2006; Yuan and Cantley, 2008). Receptor
tyrosine kinases and other signaling pathways activate PI3-
kinase, which generates phosphatidylinositol-3,4,5-trisphos-
phate (PIP3) (Yuan and Cantley, 2008). PIP3 activates Akt, which
promotes cell growth, proliferation, and survival by phosphory-
lating diverse substrates (Manning and Cantley, 2007), including
the tuberous sclerosis complex (TSC) (Inoki et al., 2002). Phos-
phorylation by Akt negatively regulates TSC, leading to theCelactivation of the mammalian target of rapamycin (mTOR) kinase
(Inoki et al., 2002). mTOR functions in two distinct complexes,
mTORC1, which is directly inhibited by rapamycin, and
mTORC2, which can be indirectly inhibited by rapamycin (Guer-
tin and Sabatini, 2007; Sarbassov et al., 2006). mTORC1 pro-
motes cell growth and proliferation by activating S6 kinase and
inactivating 4EBP1, promoting protein synthesis (Inoki et al.,
2002). mTORC2 regulates Akt activation (Guertin and Sabatini,
2007). PI3-kinase signaling is attenuated by Pten, which dephos-
phorylates PIP3 (Maehama and Dixon, 1998), reducing the
activation of Akt, mTORC1, and S6 kinase. As a result, Pten defi-
ciency increases the growth, proliferation, and survival of many
cells (Sun et al., 1999), and Pten is commonly deleted in diverse
cancers (Di Cristofano and Pandolfi, 2000).
PI3-kinase pathway signaling has divergent effects on stem
cells. Conditional deletion of Pten from embryonic stem cells
and neural stem cells increases cell cycle entry and self-renewal
(Gregorian et al., 2009; Groszer et al., 2001, 2006; Sun et al.,
1999). In contrast, Pten deletion from adult HSCs increases cell
cycle entry but this leads to rapid HSC depletion (Yilmaz et al.,
2006; Zhang et al., 2006). We showed that this depletion was
mediated by mTOR activation as rapamycin blocked the deple-
tion of Pten-deficient HSCs (Yilmaz et al., 2006). Subsequent
studies of Tsc1-deficient HSCs confirmed that increased PI3-
kinase pathway signaling can drive HSCs into cycle but that
this leads to mTOR-mediated HSC depletion (Chen et al., 2008;
Gan et al., 2008). Pml deletion also increased HSC cycling and
led to mTOR-mediated HSC depletion (Ito et al., 2008). mTOR
is thus a critical modulator of stem cell maintenance, raising the
question of how mTOR activation leads to stem cell depletion.
While Pten deletion leads to the depletion of normal HSCs, this
leads to the generation and expansion of leukemia-initiating cells
(Yilmaz et al., 2006). This makes it possible to deplete leukemia-
initiating cells while rescuing normal HSC function via rapamycin
inmice that are deficient for Pten. A sophisticated understanding
of PI3-kinase pathway signaling can therefore lead to therapies
that eliminate cancer-initiating cells with limited toxicity to nor-
mal stem cells.
One mechanism by which Pten deletion and PI3-kinase
pathway activation could deplete stem cells involves a tumorl Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier Inc. 593
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p53 and p16Ink4a Deplete Pten-Deficient Stem Cellssuppressor response. Sustained oncogenic signals can induce
tumor suppressors that cause cellular senescence (Lin et al.,
1998; Serrano et al., 1997). Conditional inactivation of Pten in
prostate leads to the induction of p53-mediated senescence,
impeding the development of prostate cancer (Chen et al.,
2005). These studies raise the question of whether a similar
tumor suppressor response occurs after Pten deletion in stem
cells and whether this suppresses leukemogenesis or depletes
HSCs.
Another mechanism by which Pten deletion could deplete
HSCs involves the inactivation of FoxO family transcription
factors. When localized to the nucleus, FoxO transcription
factors promote the expression of enzymes that eliminate
reactive oxygen species (ROS). However, activated Akt
phosphorylates FoxO proteins, leading to their retention in the
cytoplasm (Biggs et al., 1999; Brunet et al., 1999) and increasing
ROS levels. HSCs are particularly sensitive to the toxic effects of
ROS (Ito et al., 2004, 2006). Deletion of FoxO1/3/4 or FoxO3a
alone from adult HSCs leads to increased ROS levels and HSC
depletion that can be at least partially rescued by the antioxidant
N-acetyl-cysteine (NAC) (Miyamoto et al., 2007; Tothova et al.,
2007; Yalcin et al., 2008). The depletion of Tsc1-deficient
HSCs is also partly rescued by NAC treatment (Chen et al.,
2008). On the other hand, constitutively active Akt did not
increase ROS levels in HSCs and the depletion of these HSCs
could not be rescued by NAC treatment (Kharas et al., 2010).
These results raise the question of whether Pten deficiency
and FoxO deficiency deplete HSCs by similar or different
mechanisms.
We found that Pten deficiency and FoxO1/3/4 deficiency lead
to HSC depletion by different mechanisms. We were unable to
detect FoxO3a inactivation or a significant increase in ROS levels
in HSCs after Pten deletion. We were not able to rescue the
depletion of Pten-deficient HSCs by treating with NAC. Instead,
Pten deletion induced the expression of p16Ink4a and p53 in
HSCs and of p19Arf and p53 in other hematopoietic cells. Anal-
ysis of compound mutant mice revealed that deficiency for
p19Arf, for p16Ink4a/p19Arf, or for p53 (but not p16Ink4a) acceler-
ated leukemogenesis after Pten deletion. Moreover, deficiency
for p16Ink4a, for p16Ink4a/p19Arf, or for p53 (but not p19Arf) auton-
omously prolonged the reconstituting capacity of HSCs after
Pten deletion. Our results demonstrate that there are multiple
mechanisms by which increased PI3-kinase pathway signaling
can deplete HSCs, including an mTOR-mediated tumor
suppressor response that occurs in HSCs after Pten deletion
and that is attenuated by secondary mutations in leukemogenic
clones.
RESULTS
Akt Activation after Pten Deletion Activates mTORC1
but Does Not Inactivate FoxO3a
We conditionally deleted Pten from HSCs and other hematopoi-
etic cells in young adult Ptenfl/fl;Mx-1-Cre+ mice and Pten+/fl;
Mx-1-Cre+ littermate controls by administering seven doses of
polyinosine-polycytidine (pIpC) over 14 days (Yilmaz et al.,
2006). Pten-deleted mice and littermate controls were then
treated for a week with daily injections of rapamycin or vehicle.
Rapamycin treatment and Pten deletion both increased Akt594 Cell Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier Incactivation in bone marrow cells and in HSCs based on western
blotsperformed in c-kit+Flk-2LinSca-1+CD48cells, apopula-
tion highly enriched for HSCs (Figures 1A and 1B; Christensen
and Weissman, 2001; Kiel et al., 2005). The increase in Akt
phosphorylation after rapamycin treatment is consistent with
the attenuation of a negative feedback loop from S6 kinase to
IRS-1 as a result of reduced mTORC1 activation (Harrington
et al., 2004). Rapamycin does not, therefore, rescue the re-
constituting activity of Pten-deficient HSCs by normalizing Akt
activation.
Pten deletion did not appear to deplete HSCs by negatively
regulating FoxO expression. By western blot neither Pten dele-
tion nor rapamycin treatment appeared to significantly affect
total FoxO3a levels in c-kit+Flk-2LinSca-1+CD48 HSCs (Fig-
ure 1B), or phospho-FoxO3a levels, total FoxO1 levels, or phos-
pho-H2AX levels in c-kit+LinSca-1+ cells (Figure S2). In control
experiments, when CD150+CD48CD41Linc-kit+Sca-1+
HSCs (Kiel et al., 2005) were sorted from control and Pten-
deleted mice and stimulated with SCF and TPO in culture for
24 hr, they showed an overall decrease in FoxO3a staining as
well as decreased nuclear staining and increased cytoplasmic
staining (Figure S3). In contrast, when HSCs were stained imme-
diately after isolation from mice, we detected no change in
FoxO3a expression or subcellular localization after Pten deletion
(Figures 1F–1H): FoxO3a continued to localize to the nucleus.
mTORC1 activity was clearly elevated after Pten deletion
based on increased phospho-S6 levels in freshly isolated bone
marrow cells and HSCs (Figures 1A, 1B, 1D, 1E, and 1H). This
increase in phospho-S6 levels was attenuated by rapamycin
treatment (Figures 1A and 1B). These changes were further
confirmed by increased phospho-4EBP1 levels in bone marrow
cells after Pten deletion (Figure 1A). This increase in phospho-
4EBP1 levels was also attenuated by rapamycin treatment
(Figure 1A). Thus, Pten deletion increased mTORC1 and S6
kinase activation in a manner that was reversed by rapamycin,
suggesting that the changes that lead to HSC depletion after
Pten deletion are mediated by this branch of the PI3-kinase
pathway.
Pten Deletion Increases ROS Levels in Thymocytes
but Not in HSCs or Bone Marrow Cells
We assessed the intracellular levels of ROS in CD150+
CD48CD41Linc-kit+Sca-1+ HSCs, CD150CD48CD41
Linc-kit+Sca-1+ transiently reconstituting multipotent progeni-
tors (MPPs) (Kiel et al., 2008), bone marrow cells, and thymo-
cytes from Pten-deleted mice and littermate controls 1 week
after finishing pIpC treatment. After Pten deletion, we detected
a significant increase in ROS levels in thymocytes (Figures 2C
and 2E; 2.8-fold, p < 0.05) but not in bone marrow cells, HSCs,
or MPPs (Figures 2B and 2E). Three weeks after finishing pIpC
treatment, we also did not detect an increase in ROS levels
within unfractionated bone marrow cells, HSCs, or MPPs
(Figures 2D and 2F). Only mice showing no signs of neoplasms
were used in these experiments.
The increase in ROS levels in the thymus after Pten deletion
was attenuated by daily subcutaneous injection of the antioxi-
dant NAC, but NAC did not affect ROS levels in bone marrow
cells, HSCs, or MPPs (Figure 2F). It is unclear why Pten deletion
increased ROS levels in thymocytes but not in HSCs or WBM.
Figure 1. Pten Deletion Activated Akt and
mTORC1 Signaling in HSCs but FoxO3a
Was Not Inactivated
(A and B) Pten deletion increased phospho-Akt
(T308), phospho-S6, and phospho-4EBP1 (T37/46)
levels in whole bone marrow cells (A) as well as
in c-kit+Flk-2LinSca-1+CD48 HSCs (B) as ex-
pected. Rapamycin treatment tended to further
increase phospho-Akt levels, but decreased phos-
pho-S6 and phospho-4EBP1 (T37/46) levels, as
expected. Quantification demonstrated that
Pten deletion increased phospho-Akt levels by
2.6-fold and phospho-S6 levels by 1.5-fold in
HSCs. Rapamycin treatment further increased
phospho-Akt levels by 1.7-fold in HSCs and
decreased phospho-S6 levels by 40% in HSCs.
Total protein levels of FoxO3a did not decrease
withPtendeletion andwereunaffectedby rapamy-
cin treatment (B). Each lane contained protein ex-
tracted from 40,000 sorted cells.
(C–H) Staining of sorted CD150+CD48CD41
Linc-kit+Sca-1+ HSCs with secondary antibody
alone (C) or with primary and secondary antibody
against phospho-S6 (D and E) or FoxO3a (F and
G). Phospho-S6 stainingwas significantly elevated
in Ptenfl/flMx-1-Cre+ HSCs as compared to
Pten+/flMx-1-Cre+ control HSCs, as expected
(D, E, H; *p < 0.0001 by Student’s t test), but the
level and subcellular localization of FoxO3a stain-
ing did not differ between Ptenfl/flMx-1-Cre+ and
control HSCs (F–H). We analyzed 10–30 HSCs
from 1–2 mice/genotype in each of three indepen-
dent experiments. In a similar assay, culture of
HSCs in medium containing SCF and TPO did
lead to decreased total FoxO3a levels and cyto-
plasmic localization (Figure S3).
See also Figures S1–S3.
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p53 and p16Ink4a Deplete Pten-Deficient Stem Cellscells, but ROS regulation is known to differ among hematopoietic
cells (Ito et al., 2004, 2006; Tothova et al., 2007). We were also
unable to detect significant effects of Pten deletion on the
expression of FoxO target genes (Tothova et al., 2007) or antiox-
idant response genes in bone marrow cells, HSCs, or MPPs
(Figures S4C–S2H).
NAC Does Not Rescue Major Hematopoietic Defects
after Pten Deletion
Consistent with the normal ROS levels in HSCs and most other
hematopoietic cells, daily treatment with NAC for 3 weeks after
pIpC treatment did not rescue the changes in spleen, thymus, or
bone marrow cellularity after Pten deletion (Figures S4A and
S4B). NAC treatment also did not rescue the depletion of
bone marrow HSCs (Figures 2G and 2J). MPP frequency and
number in the bone marrow and spleen were not significantly
affected by Pten deletion or NAC treatment (Figures 2H, 2I,
2K, and 2L). The frequency and absolute number of HSCs and
MPPs increased significantly in the spleen 3 weeks after pIpC
treatment (Figures 2I and 2L), consistent with the extramedullary
hematopoiesis that arises after Pten deletion (Yilmaz et al.,
2006). NAC attenuated the increase in splenic HSCs, though
HSC frequency and number still increased significantly in the
spleen (Figures 2I and 2L). NAC also had little effect on other
changes in hematopoiesis after Pten deletion (Figures
S5A–S5C). The inability of NAC to rescue hematopoietic defectsCelafter Pten deletion contrasts with the ability of rapamycin to do
so (Yilmaz et al., 2006).
To test whether NAC rescues the function of Pten-deleted
HSCs, we treated Ptenfl/fl;Mx-1-Cre+ and Pten+/fl;Mx-1-Cre+
mice with seven doses of pIpC over 14 days, then transplanted
10 donor CD150+CD48CD41Linc-kit+Sca-1+ HSCs along
with a radioprotective dose of recipient bone marrow cells
into irradiated recipients. Half of the recipients received daily
subcutaneous injections of NAC, while the other half received
daily saline injections, starting on the day after transplantation.
In three independent experiments, all recipients of control
HSCs, whether treated with NAC or vehicle, were long-termmul-
tilineage reconstituted by donor cells (Figures 3A–3E). All of the
recipients of Pten-deleted HSCs showed transient multilineage
reconstitution, irrespective of whether they were treated with
NAC (Figures 3A–3E). The inability of NAC to rescue Pten-defi-
cient HSC frequency or function suggests that oxidative stress
is unlikely to be the primary determinant of HSC depletion after
Pten deletion.
To assess whether NAC treatment reduces leukemogenesis
after Pten deletion, we transplanted 1 3 106 bone marrow cells
from untreated Ptenfl/fl;Mx-1-Cre+ mice or Pten+/fl;Mx-1-Cre+
controls along with 500,000 recipient bone marrow cells into
irradiated recipients. Six weeks later, we treated the recipients
with seven doses of pIpC over 14 days followed by daily NAC
or saline injection. In two independent experiments, recipientsl Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier Inc. 595
Figure 2. Pten Deletion Significantly Increased ROS Levels in Thymocytes but Not in HSCs, MPPs, or Whole Bone Marrow Cells and NAC
Treatment Failed to Rescue the Depletion of HSCs
(A) Gating scheme used to assess intracellular ROS levels in CD150+CD48CD41Linc-kit+Sca-1+ HSCs and CD150CD48CD41Linc-kit+Sca-1+ MPPs.
(B and D) 7 (B) or 21 (D) days after finishing pIpC treatment (seven doses of pIpC over 14 days), DCFDA staining of whole bonemarrow cells, HSCs, andMPPs did
not significantly differ between Ptenfl/flMx-1-Cre+ and Pten+/flMx-1-Cre+ control mice.
(C) In contrast, thymocytes from Ptenfl/flMx-1-Cre+ mice did exhibit significantly greater DCFDA staining than thymocytes from Pten+/flMx-1-Cre+ controls.
(E) Mean DCFDA fluorescence levels showed no evidence of increased ROS levels in HSCs, MPPs, or bone marrow cells, but a significant (*p < 0.05 by Student’s
t test) increase in ROS levels within thymocytes.
(F) Similar experiments performed 21 days after finishing pIpC treatment yielded similar results. Daily subcutaneous injections of NAC after pIpC treatment did not
significantly affect DCFDA staining of HSCs, MPPs, or bone marrow cells, but did significantly reduce DCFDA staining of thymocytes.
(G and J) The frequency (G) and absolute number (J) of CD150+CD48CD41Linc-kit+Sca-1+ HSCs in the bonemarrow declined significantly after Pten deletion
but were not affected by NAC.
(H and K) The frequency (H) and absolute number (K) of CD150CD48CD41Linc-kit+Sca-1+ MPPs in the bone marrow were not affected by Pten deletion
or NAC.
(I and L) The frequency (I) and absolute number (L) of HSCs and MPPs in the spleen significantly increased after Pten deletion. The increase in HSCs was slightly
but significantly (#p < 0.05) attenuated by NAC treatment but the increase in MPPs was not significantly affected (I, L).
Data (mean ± standard deviation) are from four independent experiments with 1–2 mice/genotype/treatment. See also Figure S4.
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p53 and p16Ink4a Deplete Pten-Deficient Stem Cellsof control cells all survived for 120 days and showed no signs of
leukemogenesis (n = 20, Figure 3F). In contrast, all 20 recipients
of Pten-deleted bone marrow died with myeloproliferative596 Cell Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier Incdisease (MPD) and/or T cell acute lymphoblastic leukemia
(T-ALL) 33 to 112 days after pIpC treatment, irrespective of
whether they were treated with NAC (Figure 3F; Figures S5D–S5I)..
Figure 3. NAC Treatment Did Not Restore
the Reconstituting Capacity of HSCs or
Block Leukemogenesis after Pten Deletion
(A–E) After pIpC treatment, 10 donor CD150+
CD48CD41Linc-kit+Sca-1+ HSCs were trans-
planted into lethally irradiated recipients along
with 300,000 recipient bone marrow cells, and
recipients were maintained on daily injections of
NACor vehicle beginning the day after transplanta-
tion. Control (Pten+/flMx-1-Cre+) HSCs gave high
levels of long-term multilineage reconstitution by
donor Gr-1+ myeloid (B), CD3+ T (C), B220+ B
(D), and Mac-1+ myeloid cells (E) in all recipients,
irrespective of NAC treatment. Pten-deleted
(Ptenfl/flMx-1-Cre+) HSCs gave transient multiline-
age reconstitution in all recipients and significantly
(*p < 0.05 by Student’s t test) lower levels of donor
reconstitution in all lineages (B–E), irrespective of
NAC treatment. NAC treatment did not signifi-
cantly affect reconstitution levels from either
Pten-deleted or control HSCs. Data represent
mean ± SEM from three independent experiments.
(F) In two independent experiments, 13 106 unex-
cised donor cells from Ptenfl/flMx-1-Cre+ or
Pten+/flMx-1-Cre+ mice were transplanted into
irradiated recipient mice. Six weeks later, Pten
was deleted by pIpC treatment, and then recipi-
ents were given daily injections of NAC or vehicle.
NAC treatment did not prolong the survival of mice
or delay the onset of leukemia after Pten deletion.
None of the recipients of control cells developed
neoplasms but all mice with Pten-deficient cells
had MPD and/or T-ALL when they died, irrespec-
tive of NAC treatment.
See also Figure S5.
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p53 and p16Ink4a Deplete Pten-Deficient Stem CellsNAC treatment did not significantly affect the lifespan of mice
after Pten deletion (Figure 3F) in contrast to rapamycin, which
prevents leukemogenesis and extends the lifespan of Pten-
deleted mice (Yilmaz et al., 2006).
Pten Deletion Leads to a Tumor Suppressor Response
in HSCs
We tested whether Pten deletion induced a tumor suppressor
response by assessing the expression of p16Ink4a, p19Arf, p53,
and p21Cip1 in splenocytes. We did not detect p16Ink4a protein
expression in splenocytes with or without Pten deletion (Fig-
ure 4A). We did detect very low levels of p16Ink4a transcript in
splenocytes, but transcript levels were not significantly affected
by Pten deletion or rapamycin treatment (Figure S6A). In con-
trast, we observed clear increases in p19Arf, p53, and p21Cip1
protein after Pten deletion (Figure 4A). These increases wereCell Stem Cell 7, 593–605,attenuated or eliminated by rapamycin,
suggesting that the expression of these
tumor suppressors was elevated as a
consequence of mTOR activation (Fig-
ure 4A). We confirmed significantly in-
creased expression of p19Arf (Figure 4B)
and p21Cip1 (Figure S6B) by qPCR in
Pten-deficient splenocytes and that these
increases were eliminated by rapamycintreatment. We observed no effect of Pten deletion or rapamycin
treatment on p53 transcript levels (Figure S6C), consistent
with the observation that p53 expression is mainly regulated
posttranscriptionally (Olsson et al., 2007).
We hypothesized that this tumor suppressor response in-
hibited leukemogenesis but promoted the depletion of HSCs
after Pten deletion and that rapamycin rescued HSC depletion
by attenuating the tumor suppressor response in HSCs.
Because p16Ink4a and p19Arf are expressed at extraordinarily
low levels in primary somatic cells and only limited amounts of
protein are available from rare HSCs, we sorted 2 3 106
Linc-kit+ hematopoietic stem/progenitor cells, immunoprecipi-
tated p16Ink4a, p19Arf, and p53, then performed western blots to
assess the levels of p16Ink4a, p19Arf, and p53. We observed
p16Ink4a and p53 expression in the Pten-deficient Linc-kit+ cells
but not in wild-type cells or cells treated with rapamycin, but weNovember 5, 2010 ª2010 Elsevier Inc. 597
Figure 4. Pten Deletion Increased p19Arf,
p21Cip1, and p53 Expression in Splenocytes,
and p16Ink4a and p53 in HSCs, and Rapamy-
cin Attenuated These Increases
(A) Levels of p16Ink4a, p19Arf, p21Cip1, and p53
were assessed by western blot in unfractionated
splenocytes from Ptenfl/flMx-1-Cre+ mice and
Pten+/flMx-1-Cre+ controls 14 days after pIpC
treatment. Mice were given daily injections of ra-
pamycin or vehicle after pIpC treatment ended.
Analysis of p53-deficient MEFs (data not shown)
indicated that the upper band (#) was not specific
for p53 but the lower band was. This blot is repre-
sentative of three independent experiments.
(B) We also observed increased p19Arf transcript
levels by qPCR in splenocytes after Pten deletion
and this effect was attenuated by rapamycin
treatment (mean ± SD from three independent
experiments).
(C) 4 weeks after pIpC treatment ended, 2 3 106
Linc-kit+ stem/progenitor cells were sorted from
control and Pten-deleted mice and cell lysates
were immunoprecipitated via antibodies against
p16Ink4a, p19Arf, and p53 before western blotting.
p16Ink4a and p53 levels increased in Pten-deleted
cells, but we detected no increase in p19Arf. MEFs
that were deficient or heterozygous for p16Ink4a/
p19Arfwere used as negative and positive controls.
(D) p16Ink4a transcript could always be amplified fromPten-deficient CD150+CD48CD41Linc-kit+Sca-1+ HSCs (five of five samples) but usually not fromcontrol
(one of five) or rapamycin-treated Pten-deficient (two of five) samples 4 weeks after Pten deletion. p19Arf transcripts could only be amplified from about half of the
samples, irrespective of Pten deletion or rapamycin treatment (data are from five independent experiments).
(E andF) 4weeksafter pIpC treatment ended,CD150+CD48CD41Linc-kit+Sca-1+HSCs fromPten-deletedmiceexhibitedhigher levelsof immunofluorescence
forp53 thancontrolHSCsorPten-deletedHSCstreatedwith rapamycin. (F) Theaveragestaining intensity forp53 increased1.4-fold (*p<0.008byStudent’s t test) in
Pten-deleted HSCs as compared to control HSCs. Rapamycin treatment rescued this effect (#p < 0.003 by Student’s t test; data are from 30 HSCs per group
compiled from 2 independent experiments). None of the mice studied in this figure showed any signs of hematopoietic neoplasms.
See also Figure S6.
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p53 and p16Ink4a Deplete Pten-Deficient Stem Cellsdid not detect p19Arf expression in wild-type or Pten-deficient
Linc-kit+ cells (Figure 4C).
p16Ink4a transcript levels also increased in CD150+CD48
CD41Linc-kit+Sca-1+ HSCs after Pten deletion and this
increase was attenuated by rapamycin treatment (Figure 4D).
We were unable to detect a clear increase in p19Arf expression
after Pten deletion (Figure 4D). We also stained CD150+
CD48CD41Linc-kit+Sca-1+ HSCs with p53 antibody on
slides to assess the level of p53 expression on a cell-by-cell
basis. Pten-deficient HSCs that had not been treated with rapa-
mycin exhibited significantly increased p53 staining (Figures 4E
and 4F). Together, our results suggest that p16Ink4a and p53,
but not p19Arf, are induced in HSCs after Pten deletion.
Deficiency for p19Arf or p53, but Not p16Ink4a,
Accelerates Leukemogenesis
Conditional deletion of Pten from p16Ink4a/p19Arf-deficient or
p53-deficient backgrounds led to leukemogenesis (T-ALL,
MPD, and/or histiocytic sarcoma) and to the death of mice within
14 days of pIpC treatment, much faster than after deletion of
Pten from mice with wild-type tumor suppressors (data not
shown). To avoid the rapid death of compound mutant mice
and to compare the rates of leukemogenesis from limited
numbers of mutant cells in a wild-type environment, we trans-
planted 1 3 106 unexcised donor (CD45.2+) bone marrow cells
from wild-type, p16Ink4a/p19Arf/, Ptenfl/fl;Mx-1-Cre+, and
Ptenfl/fl;Mx-1-Cre+;p16Ink4a/p19Arf/ mice into irradiated wild-598 Cell Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier Inctype recipient mice along with 500,000 recipient (CD45.1+)
bone marrow cells. Six weeks after transplantation, when the
donor cells had stably engrafted, all recipients were treated
with seven injections of pIpC over 14 days to induce Pten dele-
tion. Recipients of wild-type and p16Ink4a/p19Arf/ bonemarrow
cells almost all survived for the duration of the experiment
(165 days) with no signs of leukemogenesis (Figure 5A). In con-
trast, recipients of Ptenfl/fl;Mx-1-Cre+ cells died 49 to 162 days
after ending pIpC treatment (Figure 5A). Recipients of Ptenfl/fl;
Mx-1-Cre+;p16Ink4a/p19Arf/ cells died significantly (p < 0.02)
more quickly, 27 to 65 days after ending pIpC treatment (Fig-
ure 5A). Histology confirmed that the mice had MPD and/or
histiocytic sarcoma and/or T-ALL when they died. These data
indicate that deficiency for p16Ink4a and p19Arf accelerates leuke-
mogenesis after Pten deletion.
To better understand the relative contributions of p16Ink4a and
p19Arf to the suppression of leukemogenesis after Pten deletion,
we performed the same experiment with mice that were
compound mutants for Pten and p16Ink4a (Figure 5C) or Pten
and p19Arf (Figure 5B). p16Ink4a deficiency did not significantly
affect the rate at which mice died or the spectrum of hematopoi-
etic neoplasms that arose after pIpC treatment (Figure 5C).
In contrast, p19Arf deficiency did significantly (p < 0.02) increase
the rate at which mice died after pIpC treatment (Figure 5B).
These results suggest that p19Arf suppresses leukemogenesis
after Pten deletion, consistent with the increase in p19Arf expres-
sion in splenocytes after Pten deletion (Figure 4A)..
Figure 5. Deficiency for p19Arf or p53, but
Not p16Ink4a, Accelerated Leukemogenesis
after Pten Deletion
1 3 106 donor bone marrow cells from mice with
the indicated genotypes were transplanted into
irradiated recipient mice along with 500,000
recipient bonemarrow cells. Six weeks after trans-
plantation, all recipients were treated with pIpC
and their survival was monitored over time (up to
165 days after pIpC treatment ended).
(A) Recipients of Ptenfl/flMx-1-Cre+p16Ink4a/
p19Arf/ cells (displayed as PtenD/Dp16Ink4a/
p19Arf/) exhibited significantly (*p < 0.02 by
Student’s t test) accelerated death as compared
to recipients of Ptenfl/flMx-1-Cre+ cells (PtenD/D).
Mice were sacrificed when moribund and their
hematopoietic tissues analyzed. The neoplasms
observed in each mouse at the time of sacrifice
included myeloproliferative disease (MPD),
T-ALL, MPD+T-ALL, histiocytic sarcoma (HS),
and HS+T-ALL.
(B) Recipients of Ptenfl/flMx-1-Cre+p19Arf/ cells
(PtenD/Dp19Arf/) exhibited significantly (*p <
0.02 by log-rank test) accelerated death from
leukemogenesis as compared to recipients of
Ptenfl/flMx-1-Cre+ cells (PtenD/D).
(C)RecipientsofPtenfl/flMx-1-Cre+p16Ink4a (PtenD/D
p16Ink4a) cells died at a similar rate and with similar
neoplasms as recipients of Ptenfl/flMx-1-Cre+ cells
(PtenD/D).
(D) Recipients of Ptenfl/flMx-1-Cre+p53/ cells
(PtenD/Dp53/) exhibited significantly (**p <
0.0001 by log-rank test) accelerated death from
leukemogenesis as compared to recipients of
Ptenfl/flMx-1-Cre+ cells (PtenD/D). Data are from 3
independent experiments with a total of 9 mice/
genotype except for compound mutant mice,
which had 14–20 mice/genotype.
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p53 and p16Ink4a Deplete Pten-Deficient Stem CellsTo assess the role of p53, we performed the same experiment
with mice that were compound mutant for Pten and p53 (Fig-
ure 5D). Recipients of Ptenfl/fl;Mx-1-Cre+;p53/ cells died
much more quickly after pIpC treatment as compared to recipi-
ents of Ptenfl/fl;Mx-1-Cre+ cells (p < 0.0001; Figure 5D). All mice
were confirmed to have MPD, AML, and/or T-ALL when they
died (Figure 5D). These results suggest that p53 suppresses
leukemogenesis after Pten deletion.
p16Ink4a and p53 Promote the Depletion of HSCs after
Pten Deletion
To test whether the tumor suppressors that inhibit leukemogen-
esis after Pten deletion also act cell autonomously within HSCs
to promote their depletion, we transplanted 10 donor CD150+C
D48CD41Linc-kit+Sca-1+ HSCs from mice with each of the
genetic backgrounds depicted in Figure 6 into irradiated wild-
type recipient mice, along with a radioprotective dose of
300,000 recipient bone marrow cells. The HSCs were isolated
from the donor mice after they had been treated with three injec-
tions of pIpC over 6 days.
p16Ink4a deficiency prolonged the reconstituting capacity of
Pten-deficient HSCs. Wild-type and p16Ink4a-deficient
HSCs gave long-term multilineage reconstitution by donor cells
in all recipient mice (Figure 6A). In contrast, Pten-deleted
(Ptenfl/flMx-1-Cre+) HSCs only gave transient multilineage recon-Celstitution for 6 to 8 weeks after transplantation, consistent with
our prior study (Yilmaz et al., 2006). Surprisingly, compound
mutant Ptenfl/flMx-1-Cre+p16Ink4a/ HSCs gave significantly
longer multilineage reconstitution than Ptenfl/flMx-1-Cre+ HSCs
(for 8 to 16 weeks, p < 0.002; Figure 6A) with significantly higher
donor cell reconstitution levels than the levels of reconstitution
from Ptenfl/flMx-1-Cre+ HSCs (Figure 6A). Sixteen weeks after
transplantation, four recipients of Ptenfl/flMx-1-Cre+p16Ink4a/
HSCs remained alive and two of these mice remained multiline-
age reconstituted by donor cells. In a separate experiment, we
confirmed that CD150+CD48CD41Linc-kit+Sca-1+ donor
HSCs (Figure 6E) and CD150CD48CD41Linc-kit+Sca-1+
donor MPPs (Figure 6G) could be recovered 8 weeks after
transplantation from mice transplanted with 10 Ptenfl/flMx-
1-Cre+p16Ink4a/ HSCs but not those with 10 Ptenfl/flMx-
1-Cre+ HSCs. These data indicate that p16Ink4a promotes the
depletion of Pten-deficient HSCs.
Recipient mice that were transplanted with Ptenfl/flMx-
1-Cre+p16Ink4a/ HSCs did begin to die with MPD and/or
T-ALL 12 to 16 weeks after transplantation whereas recipients
of Ptenfl/flMx-1-Cre+ HSCs did not develop neoplasms (Fig-
ure 6A). This difference partly reflects the fact that Ptenfl/flMx-
1-Cre+HSCsno longer hadanydonor cell chimerismby12weeks
after transplantation and therefore were unable to develop donor
cell leukemias (Figure 6A). Therefore, p16Ink4a deficiencyl Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier Inc. 599
Figure 6. Deficiency for p16Ink4a or p53
Prolonged the Reconstituting Capacity of
Pten-Deficient HSCs
(A) 10 CD150+CD48CD41Linc-kit+Sca-1+ cells
were sorted from mice with each of the indicated
genotypes after pIpC treatment and coinjected
with 300,000 recipient bone marrow cells into irra-
diated recipient mice. The survival, donor cell
reconstitution levels (mean ± SEM), and per-
centage of surviving recipients with multilineage
reconstitution by donor cells were monitored for
16 weeks after transplantation.
(A–D) In all experiments, recipients of wild-type
cells (A–D) and recipients of p16Ink4a-deficient
cells (A), p19Arf-deficient cells (B), p16Ink4a/
p19Arf-deficient cells (C), or p53-deficient cells
(D) survived for the duration of the experiment
and showed high levels of long-term multilineage
reconstitution by donor cells. In contrast, recipi-
ents of Pten-deficient cells showed only transient
multilineage reconstitution for 4 to 8 weeks in
each experiment (A–D). HSCs that were com-
pound mutant for Pten in addition to p16Ink4a (A),
p16Ink4a/p19Arf (C), or p53 (D) gave significantly
(#p < 0.05 by Student’s t test) higher levels of
donor cell reconstitution and multilineage recon-
stitution for a significantly longer period of time
as compared to HSCs that were deficient only
for Pten. The degree of donor cell reconstitution
provided by Ptenfl/fl;Mx-1-Cre+;p16Ink4a cells (A)
did not significantly differ from Ptenfl/fl;Mx-
1-Cre+;p16Ink4a/p19Arf cells (C). p19Arf deficiency
did not significantly affect the duration or level of
reconstitution by Pten-deficient HSCs (B).
Compound mutant mice that died had MPD,
T-ALL, and/or histiocytic sarcoma at the time of
death. All data are from 3 independent experi-
ments with a total of 7–17 recipients per treatment.
(E–H) Mice were transplanted with mutant HSCs as described above then sacrificed 8 weeks later to assess the frequency of donor CD150+CD48CD41
Linc-kit+Sca-1+ HSCs and CD150CD48CD41Linc-kit+Sca-1+ MPPs. Donor HSCs and MPPs were not detectable by this time point in the absence
of Pten but depletion was rescued by either p16Ink4a deficiency (E, G) or p53 deficiency (F, H; *p < 0.05 by Student’s t test). These data are from three independent
experiments with a total of three to eight recipients per treatment. Consistent with Figure 6, transplantation of higher doses of Pten-deficient CD150+
CD48CD41Linc-kit+Sca-1+ cells into irradiated wild-type mice led to the development of leukemia in a higher proportion of the recipient mice (Table S1).
See also Figure S7 and Table S1.
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p53 and p16Ink4a Deplete Pten-Deficient Stem Cellsincreased the opportunity for leukemogenesis by prolonging the
reconstituting capacity of Pten-deleted HSCs. These data might
also reflect a limited role for p16Ink4a in the suppression of leuke-
mogenesis after Pten deletion.
p19Arf deficiency did not rescue the depletion ofPten-deficient
HSCs. Wild-type and p19Arf-deficient HSCs gave long-termmul-
tilineage reconstitution by donor cells in all recipient mice
(Figure 6B). In contrast, Pten-deleted (Ptenfl/flMx-1-Cre+) HSCs
gave only transient multilineage reconstitution for 6 to
8 weeks after transplantation. Compound mutant Ptenfl/flMx-
1-Cre+p19Arf/ HSCs also gave transient multilineage reconsti-
tution for only 4 to 8 weeks and at levels that were not signifi-
cantly different from those observed from Ptenfl/flMx-1-Cre+
HSCs (Figure 6B). This indicates that p19Arf is not required for
the depletion of HSCs after Pten deletion, consistent with our
failure to detect p19Arf expression in Pten-deficient HSCs
(Figures 4C and 4D). Only a minority of recipients of Ptenfl/flMx-
1-Cre+p19Arf/ HSCs died with leukemia (beginning 8 weeks
after transplantation), reflecting the transient reconstitution by
these cells (Figure 6B).600 Cell Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier IncConsistent with the partial rescue of HSC depletion by p16Ink4a
deficiency,wealsoobserved apartial rescueofHSCdepletion by
p16Ink4a/p19Arf deficiency. Wild-type and p16Ink4a/p19Arf-defi-
cient HSCs gave long-term multilineage reconstitution by donor
cells in almost all recipient mice (Figure 6C). In contrast, Pten-
deleted (Ptenfl/flMx-1-Cre+) HSCs gave only transient multiline-
age reconstitution for 4 to 8 weeks after transplantation.
Compound mutant Ptenfl/flMx-1-Cre+p16Ink4a/p19Arf/ HSCs
gave significantly longer multilineage reconstitution than
Ptenfl/flMx-1-Cre+HSCs (for up to 14weeks, p < 0.01; Figure 6C),
with significantly higher donor cell reconstitution levels than from
Ptenfl/flMx-1-Cre+HSCs (Figure 6C). These results are consistent
with the data above in suggesting that p16Ink4a depletes HSCs
after Pten deletion. There were no statistically significant differ-
ences in the extent to which reconstitution was rescued by
p16Ink4a deficiency as compared to p16Ink4a/p19Arf deficiency,
although p16Ink4a/p19Arf deletion was more leukemogenic (Fig-
ures 6A and 6C).
p53 deficiency also prolonged the reconstituting capacity of
Pten-deficient HSCs. Wild-type and p53-deficient HSCs gave.
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p53 and p16Ink4a Deplete Pten-Deficient Stem Cellslong-term multilineage reconstitution by donor cells in all
recipient mice for at least 16 weeks whereas Pten-deleted
(Ptenfl/flMx-1-Cre+) HSCs gave transient multilineage reconstitu-
tion for 4 to 6 weeks after transplantation (Figure 6D). Compound
mutant Ptenfl/flMx-1-Cre+p53/ HSCs gave significantly longer
multilineage reconstitution than did Ptenfl/flMx-1-Cre+ HSCs
(for up to 12 weeks, p < 0.002; Figure 6D), with significantly
higher donor cell reconstitution levels than from Ptenfl/flMx-
1-Cre+ HSCs (Figure 6D). In a separate experiment, we
confirmed that donor HSCs (Figure 6F) and MPPs (Figure 6H)
could be recovered 8 weeks after transplantation of 10
Ptenfl/flMx-1-Cre+p53/ HSCs but not after transplantation of
10 Ptenfl/flMx-1-Cre+ HSCs. p53 therefore contributes to the
depletion of Pten-deficient HSCs in addition to suppressing
leukemogenesis, consistent with its increased expression after
Pten deletion in splenocytes and HSCs (Figure 4).
The precise mechanisms by which p16Ink4a and p53 promote
the depletion of HSCs after Pten deletion are uncertain. We did
not detect any effect of Pten deletion or rapamycin treatment
on the frequency of whole bone marrow cells or HSCs under-
going cell death (Figure S7A) or expressing senescence-associ-
ated b-galactosidase (Figures S7C–S7E). Indeed, we observed
an increase in the frequency of dividing HSCs after Pten deletion
(rather than a decrease as would be expected if senescence
were occurring), and this increase was rescued by rapamycin
treatment (Figure S7B). These results suggest that increased
p16Ink4a and p53 expression in dividing HSCs is incompatible
with HSC maintenance, perhaps because these tumor suppres-
sors promote maturation out of the stem cell pool.
Pten-Deficient Leukemias Have Mutations that
Attenuate the Tumor Suppressor Response
To test whether Pten-deficient leukemias acquire secondary
mutations that attenuate the tumor suppressor response, we
tested whether there was a selection pressure to inactive p53
in these leukemias. The tumor suppressors could be attenuated
by many mechanisms that would silence or inactivate the tumor
suppressors or other genes in the same pathways. Because it
would be impossible to test all such mechanisms, we circum-
vented this problem by studying leukemogenesis in a sensitized,
p53 heterozygous background. If there is selective pressure to
inactivate p53 in Pten-deficient leukemias, leukemias should
arise more quickly from p53+/ mice as compared to p53+/+
mice, and we would expect the leukemias to delete the wild-
type p53 allele. Young adult wild-type, p53+/, Ptenfl/fl;Mx-
1-Cre+;p53+/+, and Ptenfl/fl;Mx-1-Cre+;p53+/ mice were treated
with pIpC andmonitored. Wild-type and p53+/mice all survived
for the duration of the experiment (50 days) with no signs of
leukemia, whereas Ptenfl/fl;Mx-1-Cre+;p53+/+ mice died 21 to
45 days after pIpC treatment with T-ALL and MPD (Figure 7A).
Ptenfl/fl;Mx-1-Cre+;p53+/ mice died significantly (p = 0.0008)
more quickly, 8 to 39 days after ending pIpC treatment, again
with T-ALL and MPD (Figure 7A). Heterozygosity for p53 there-
fore accelerates leukemogenesis.
We next examined p53 expression in the thymus of mice that
developed leukemias. In each case, the thymus was enlarged,
completely effaced, and appeared to consist mainly of
leukemic lymphoblasts. Whereas thymocytes from Ptenfl/fl;Mx-
1-Cre+;p53+/+ mice showed robust expression of p53 (six of sixCelsamples), thymyocytes from Ptenfl/fl;Mx-1-Cre+;p53+/ mice
showed little or no p53 expression (four of four samples; Fig-
ure 7B). PCR amplification of genomic DNA showed that thymic
lymphoblasts from all four Ptenfl/fl;Mx-1-Cre+;p53+/ mice had
deleted the wild-type allele of p53 (Figure 7C). Thus, Pten dele-
tion induces a strong selective pressure to inactivate the tumor
suppressor response in leukemogenic cells.
DISCUSSION
Pten deletion increased Akt, mTORC1, and S6 kinase activation
in HSCs (Figures 1B, 1D, and 1E) but we could find no evidence
for reduced FoxO1 or FoxO3a expression or cytoplasmic
sequestration (Figures 1B and 1F–1H; Figure S2). We observed
a clear increase in ROS levels within thymocytes after Pten dele-
tion but not in HSCs (Figure 2). Consistent with this, NAC treat-
ment attenuated the increase in ROS levels in thymocytes but
did not rescue the changes in hematopoiesis, HSC frequency
(Figure 2), or HSC reconstituting capacity (Figure 3A) after Pten
deletion. This contrasted with results from FoxO1/3/4-deficient
mice in which ROS levels clearly increased within HSCs and
NAC treatment at least partially rescued HSC depletion (Tothova
et al., 2007). Pten deletion and FoxO1/3/4 deletion thus lead to
the depletion of HSCs by different mechanisms. HSC depletion
after Pten deletion is mediated largely by mTOR activation with
no evidence so far for an important contribution by oxidative
stress.
Pten deletion induced a tumor suppressor response in hema-
topoietic cells, characterized by increased expression of p19Arf
and p53 in splenocytes (Figures 4A and 4B) and increased
expression of p16Ink4a and p53 in HSCs (Figures 4C–4F).
p16Ink4a/p19Arf deficiency, p19Arf deficiency, or p53 deficiency
significantly accelerated leukemogenesis after Pten deletion
(Figures 5A, 5B, and 5D). p16Ink4a deficiency did not significantly
affect the rate of leukemogenesis after Pten deletion, though it
did suppress the generation of histiocytic sarcomas (Figure 5C).
This suggests that hematopoietic cells mainly rely upon the p53
pathway to suppress leukemogenesis after Pten deletion. This is
consistent with results from mouse prostate in which Pten dele-
tion induces p53-dependent senescence (Chen et al., 2005).
Interestingly, this senescence response is p19Arf independent
in prostate (Chen et al., 2009) but p19Arf did suppress leukemo-
genesis after Pten deletion, indicating tissue-specific functions
for p19Arf in tumor suppression.
p16Ink4a deficiency, p16Ink4a/p19Arf deficiency, or p53 defi-
ciency all significantly prolonged the ability of Pten-deficient
HSCs to give multilineage reconstitution in irradiated mice (Fig-
ure 6). p19Arf deficiency did not prolong the reconstituting
capacity of Pten-deficient HSCs (Figure 6B). Thus, p19Arf is crit-
ical for the suppression of leukemogenesis but not for HSC
depletion after Pten deletion. In contrast, p16Ink4a is critical for
HSC depletion but plays a limited role suppressing leukemogen-
esis. One possible explanation for this distinction is that some
leukemiasmay arise from cells other than HSCs and this process
could be inhibited by p19Arf expression in those cells.
Our results thus indicate that Pten deletion induces an mTOR-
mediated tumor suppressor response in hematopoietic cells,
suppressing leukemogenesis and depleting HSCs. This
suggests that leukemias probably arise from rare clones ofl Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier Inc. 601
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Figure 7. Some Pten-Deficient Leukemias
Inactivate p53
(A) Wild-type, p53+/, Ptenfl/fl;Mx-1-Cre+;p53+/+,
and Ptenfl/fl;Mx-1-Cre+;p53+/ mice 5 to 6 weeks
of age were treated with three doses of pIpC
then monitored. Ptenfl/fl;Mx-1-Cre+;p53+/ mice
died significantly more quickly than Ptenfl/fl;
Mx-1-Cre+;p53+/+ mice (p = 0.0008 by log-rank
test).
(B) Western blotting of thymocytes from Ptenfl/fl;
Mx-1-Cre+;p53+/+ and Ptenfl/fl;Mx-1-Cre+;p53+/
mice with T-ALL showed strongly diminished
expression of p53 in the Ptenfl/fl;Mx-1-Cre+;p53+/
cells.
(C) Genomic PCR analysis of thymocytes from
Ptenfl/fl;Mx-1-Cre+;p53+/ mice showed a signifi-
cantly diminished band corresponding to the
wild-type p53 allele suggesting loss of heterozy-
gosity. The weak wild-type p53 band may reflect
residual normal thymocytesor thymic stromal cells.
9–12 mice/genotype were used in this experiment.
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p53 and p16Ink4a Deplete Pten-Deficient Stem CellsPten-deficient hematopoietic cells that acquire secondary muta-
tions that attenuate the tumor suppressor response. Consistent
with this, we observed loss of p53 heterozygosity in leukemias
that arose from Ptenfl/fl;Mx-1-Cre+;p53+/ mice, indicating that
Pten deletion imposes a strong selection against the tumor
suppressor response (Figure 7). It is also important to note that
we do not know which hematopoietic cells are transformed after
Pten deletion. Therefore, the tumor suppressors may act in
HSCs themselves to suppress leukemogenesis or they may act
in downstream cells.
Although p16Ink4a and p19Arf are both encoded at the Cdkn2a
locus, they are regulated by different promoters, have no
sequence homology, and have different molecular functions
(Sherr, 2001). The mechanisms by which Pten deletion or other
oncogenic stimuli induce these tumor suppressor expressions
are not understood. Although it is well established that onco-
genic stresses such as c-Myc or E1A expression also activate
the p19Arf-p53 pathway (de Stanchina et al., 1998; Zindy et al.,
1998), the mechanisms behind this activation remain unclear.
The mechanisms behind p16Ink4a and p53 activation in response
to Ras activation also remain unknown (Serrano et al., 1997).
The best-characterized consequences of p53 or p16Ink4a acti-
vation are senescenceandapoptosis.However, these responses
have been characterized only in certain non-stem cell popula-
tions, and it is possible that p53 or p16Ink4a activation may have
other effects on stem cells. We did not detect any evidence that
hematopoietic cells underwent senescence or cell death after
Pten deletion (Figure S7). However, HSCs are asynchronously
depleted over a 4 to 8 week period after Pten deletion (Figure 6).
This raises the formal possibility that HSCs asynchronously
undergo cell death or senescence over 4 to 8 weeks, such that
very few HSCs express markers of cell death or senescence at
any single time point, rendering it undetectable. Nonetheless,
the simplest interpretation of our data is that p16Ink4a and p53602 Cell Stem Cell 7, 593–605, November 5, 2010 ª2010 Elsevier Inc.expression cause HSCs to prematurely
exit the stem cell pool, perhaps by
maturing to transit amplifying MPPs. This
would occur asynchronously over time,so the number of HSCs that prematurely exit the stem cell pool
at any single time point would be imperceptibly small but the
cumulative effect of prematurematuration over a period ofweeks
would deplete HSCs.
Consistent with this model, deficiency for p16Ink4a, p19Arf, and
p53 dramatically expands the frequency of long-term multiline-
age reconstituting cells by conferring long-term self-renewal
potential to MPPs that normally give only transient multilineage
reconstitution (Akala et al., 2008; Kiel et al., 2008). These tumor
suppressors thus play a physiological role promoting the transi-
tion from HSCs to MPPs and negatively regulating the self-
renewal potential of multipotent cells. Increased expression of
p16Ink4a and p53 in dividing HSCs after Pten deletion may accel-
erate the normal maturation of cells out of the HSC pool, leading
to HSC depletion.
The ability to rescue the hematopoietic phenotypes in Pten-
deficient mice with rapamycin suggests that these phenotypes
are driven by mTORC1 activation. However, our data indicate
only that increased mTORC1 activation is required for HSC
depletion and leukemogenesis, not that it is sufficient. This
may explain why other genetic backgrounds that activate
mTORC1, such as Tsc1 deletion (Chen et al., 2008; Gan et al.,
2008), do not necessarily lead to leukemogenesis. mTORC1-
independent pathways downstream of Pten presumably also
contribute to leukemogenesis. Because rapamycin can indi-
rectly inhibit mTORC2 in addition to mTORC1 (Sarbassov
et al., 2006) and mTORC2 is required for the development of
prostate cancer after Pten deletion (Guertin et al., 2009),
mTORC2 may mediate some of the effects of Pten deletion on
HSCs and other hematopoietic cells.
The depletion of HSCs (and other hematopoietic progenitors)
after Pten deletion may explain why few leukemias exhibit Pten
deletion (Aggerholm et al., 2000; Chang et al., 2006; Sakai
et al., 1998) other than T-ALL (Gutierrez et al., 2009). Rare clones
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p53 and p16Ink4a Deplete Pten-Deficient Stem Cellsof Pten-deficient hematopoietic stem/progenitor cells would be
unlikely to have the opportunity to acquire secondary mutations
before being depleted and therefore would be unlikely to prog-
ress to leukemia. Leukemias may be more likely to hyperactivate
the PI3-kinase pathway by other types of mutations that are
better tolerated by hematopoietic cells. Additional studies of
the PI3-kinase pathway in stem cells will provide additional
insights into stem cell regulation and the development of cancer.
EXPERIMENTAL PROCEDURES
Mice
C57BL/Ka-Thy-1.1 (CD45.2) and C57BL/Ka-Thy-1.2 (CD45.1) mice were used
in hematopoietic reconstitution experiments. Mx-1-Cre+ mice (Kuhn et al.,
1995), Ptenfl/fl mice (Groszer et al., 2001), Ink4a+/ mice (Sharpless et al.,
2001), Arf+/ mice (Kamijo et al., 1997), Ink4a/Arf+/ mice (Serrano et al.,
1996), and p53+/ mice (Jacks et al., 1994) were backcrossed for at least 10
generations onto a C57BL/Ka background. All mice were housed in the Unit
for Laboratory Animal Medicine at the University of Michigan. All animal proce-
dures were reviewed and approved by the University of Michigan Committee
on the Use and Care of Animals.
pIpC, Rapamycin, and N-Acetyl-L-Cysteine Administration
Polyinosine-polycytidine (pIpC) and rapamycin were administered as previ-
ously described (Yilmaz et al., 2006). In brief, pIpC from Sigma (St. Louis,
MO) or from Amersham (Piscataway, NJ) was resuspended in Dulbecco’s
phosphate-buffered saline (D-PBS) at 2 mg/ml (for Sigma) or 50 mg/ml (for
Amersham), and mice were injected intraperitoneally (i.p.) with 25 mg/gram
(for Sigma) or 0.5 mg/gram (for Amersham) of body mass every other day for
6–14 days. Rapamycin (LC Laboratories, Woburn, MA) was dissolved in abso-
lute ethanol at 10mg/ml and diluted in 5%Tween-80 (Sigma) and 5%PEG-400
(Hampton Research, Aliso Viejo, CA) before being administered daily by i.p.
injection at a dose of 4 mg/kg. N-Acetyl-L-cysteine (NAC; Sigma) was admin-
istered daily by subcutaneous injection at 100 mg/kg (pH 7.0) starting 1 day
after the final dose of pIpC.
Flow Cytometry and HSC Isolation
Bone marrow cells were obtained by crushing the long bones (tibias and
femurs), pelvic bones, and vertebrae in a mortar and pestle with Hank’s
buffered salt solution without calcium or magnesium, supplemented with
2% heat-inactivated calf serum (GIBCO, Grand Island, NY; HBSS+). Cells
were triturated and filtered through nylon screen (45 mm, Sefar America,
Kansas City, MO) to obtain a single-cell suspension. For isolation of
c-kit+Flk2LinSca-1+CD48 cells, whole bone marrow cells were incubated
with FITC-conjugated monoclonal antibodies to lineage markers including
B220 (6B2), CD3 (KT31.1), CD4 (GK1.5), CD5 (53-7.3), CD8 (53-6.7), Gr-1
(8C5), Mac-1 (M1/70), and Ter119 (TER-119) in addition to APC-conjugated
anti-Sca-1 (Ly6A/E; E13-6.7), biotin-conjugated anti-c-kit (2B8), and PE/
Cy5-conjugated anti-Flk-2 (A2F10.1). Biotin-conjugated c-kit staining was
visualized with streptavidin APC-Cy7.
For isolation of CD150+CD48CD41LinSca-1+c-kit+ HSCs, bone
marrow cells were incubated with PE-conjugated anti-CD150 (TC15-
12F12.2; BioLegend, San Diego, CA), FITC-conjugated anti-CD48 (HM48-1;
BioLegend), FITC-conjugated anti-CD41 (MWReg30; BD PharMingen, San
Diego, CA), APC-conjugated anti-Sca-1 (Ly6A/E; E13-6.7), and biotin-conju-
gated anti-c-kit (2B8) antibody, in addition to antibodies against the following
FITC-conjugated lineage markers: CD2 (RM2-5), B220 (6B2), CD3 (KT31.1),
CD5 (53-7.3), CD8 (53-6.7), Gr-1 (8C5), and Ter119 (TER-119). Biotin-conju-
gated c-kit was visualized with streptavidin-conjugated APC-Cy7. HSCs
were sometimes pre-enriched by selecting c-kit+ cells with paramagnetic
anti-biotin microbeads and autoMACS (Miltenyi Biotec, Auburn, CA). Dead
cells were excluded with the viability dye 40,6-diamidino-2-phenylindole
(DAPI) (1 mg/ml).
To measure ROS levels, bone marrow cells were isolated and stained as
above except that the HSC stain wasmodified to make the FITC channel avail-
able for DCFDA (20-70-dichlorofluorescein diacetate, Molecular Probes,CelEugene, OR) staining. Antibodies for HSC isolation were as described above
except for the following antibodies: PE/Cy5-conjugated anti-CD150 (TC15-
12F12.2; BioLegend), PE-conjugated anti-CD48 (HM48-1; BioLegend), PE-
conjugated anti-CD41 (MWReg30; BD PharMingen), and PE-conjugated anti-
bodies against lineage markers. After antibody staining, thymus cells, whole
bone marrow cells, or c-kit+ enriched cells were incubated with 5 mM DCFDA
for 15 min at 37C followed by flow cytometry.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
(details regarding immunofluorescence assays, western blotting, and quanti-
tative PCR), seven figures, and one table and can be found with this article
online at doi:10.1016/j.stem.2010.09.015
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